Since our inception, we have made significant investments in our capacity and capabilities across the drug discovery, development and manufacturing value chain. This strategy has enabled us build collaborative, long-term relationships with our clients and deliver better value to all our stakeholders.
Initiated operations as a CRO with services in chemistry and biology
Granted 100% Export-Oriented Unit (EOU) status by the Government of India
Achieved first operational expansion in R&D with lab space increased to over 23,000 sq. ft.
Forayed into Chemical Development with a dedicated manufacturing facility
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
Signed a contract with Bristol-Myers Squibb for setting up our first dedicated R&D centre
Expanded research laboratory infrastructure to 148,000 sq. ft.
Crossed an annual turnover of Rs. 1,000 Mn
Expanded manufacturing services with a new cGMP (Current Good Manufacturing Practices) plant
Initiated operations in Safety Assessment Services, Formulation Development and Biologics Development Services
Collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer
Established Abbott’s first nutrition R&D centre in India
Received ANVISA Certification for clinical facilities
Acquired 100% stake in Clinigene International Limited, a clinical research company
Crossed an annual turnover of Rs. 5,000 Mn
Established dedicated R&D centre for Baxter International Inc.
Syngene Control Testing Laboratory accepted by the Department of Health & Human Services, USFDA
Extended collaboration with Bristol-Myers Squibb for its dedicated R&D centre till 2020
Syngene API manufacturing facility accepted by the Department of Health & Human Services, USFDA
Established a 75,000 sq. ft. centre to provide stability and analytical services
Syngene listed on BSE (Bombay Stock Exchange) and NSE (National Stock Exchange) of India
Clinigene International, amalgamated with Syngene
Acquired Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expanded into Bioinformatics and NGS Services
Established dedicated R&D centre for Amgen Inc.
Crossed an annual turnover of Rs. 10,000 Mn
Strategic collaboration with Zoetis to develop and manufacture animal medicines
Collaborated with Herbalife to establish its first nutrition R&D centre in India
Broadened research collaboration with Amgen Inc., leading to expansion of facilities
Extended contract with Bristol-Myers Squibb till 2026
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
Received PMDA Accreditation
Expanded collaboration with Baxter International Inc. till 2024
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Centre for Advanced Protein Studies (CAPS)